Role of Neuroimaging on Differentiation of Parkinson’s Disease and Its Related Diseases by Ogawa, Toshihide et al.
鳥取大学研究成果リポジトリ
Tottori University research result repository
タイトル
Title
Role of Neuroimaging on Differentiation of
Parkinson’s Disease and Its Related Diseases
著者
Auther(s)
Ogawa, Toshihide; Fujii, Shinya; Kuya, Keita; Kitao,
Shin-ichiro; Shinohara, Yuki; Ishibashi, Mana; Tanabe,
Yoshio
掲載誌・巻号・ページ
Citation
Yonago Acta Medica , 61 (3) : 145 - 155
刊行日
Issue Date
2018
資源タイプ
Resource Type
学術雑誌論文 / Journal Article
版区分
Resource Version
出版社版 / Publisher
権利
Rights
注があるものを除き、この著作物は日本国著作権法により保
護されています。
DOI
URL http://repository.lib.tottori-u.ac.jp/5731
145
Yonago Acta Medica 2018;61:145–155 Review Article: Special Contribution
Corresponding author: Toshihide Ogawa, MD, PhD 
ogawa@med.tottori-u.ac.jp
Received 2018 June 20
Accepted 2018 August 10
Abbreviations: AD, Alzheimer’s disease; CBD, corticobasal 
degeneration; DaT, dopamine transporter; DaTSCAN, dopamine 
transporter SPECT; DLB, dementia with Lewy bodies; DTI, 
diffusion-tensor imaging; ET, essential tremor; FLAIR, 
fluid-attenuated inversion recovery; FDG, 18F-fluorodeoxyglucose; 
FP-CIT, 123I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) 
nortropane; HMPAO, 99mTc-hexamethyl propylene amine oxime; 
MIBG, 123I-metaiodobenzylguanidine; MSA, multiple system 
atrophy; NmMRI, neuromelanin-sensitive MR imaging; PD, 
Parkinson’s disease; PET, positron emission computed tomography; 
PSP, progressive supranuclear palsy; SPECT, single photon emis-
sion computed tomography; VBM, voxel-based morphometry; VP, 
vascular parkinsonism
Role of Neuroimaging on Differentiation of Parkinson’s Disease and Its Related 
Diseases
Toshihide Ogawa, Shinya Fujii, Keita Kuya, Shin-ichiro Kitao, Yuki Shinohara, Mana Ishibashi and Yoshio 
Tanabe
Division of Radiology, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of 
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ABSTRACT
An accurate diagnosis of Parkinson’s disease (PD) is 
a prerequisite for therapeutic management. In spite 
of recent advances in the diagnosis of parkinsonian 
disorders, PD is misdiagnosed in between 6 and 25% of 
patients, even in specialized movement disorder centers. 
Although the gold standard for the diagnosis of PD is a 
neuropathological assessment, neuroimaging has been 
playing an important role in the differential diagnosis 
of PD and is used for clinical diagnostic criteria. In 
clinical practice, differential diagnoses of PD include 
atypical parkinsonian syndromes such as dementia 
with Lewy bodies, multiple system atrophy, progressive 
supranuclear palsy, corticobasal degeneration, caused 
by a striatal dopamine deficiency following nigrostrial 
degeneration. PD may also be mimicked by syndromes 
not associated with a striatal dopamine deficiency such 
as essential tremor, drug-induced parkinsonism, and 
vascular parkinsonism. Moreover, difficulties are asso-
ciated with the clinical differentiation of patients with 
parkinsonism from those with Alzheimer’s disease. In 
this review, we summarize the typical imaging findings 
of PD and its related diseases described above using 
morphological imaging modalities (conventional MR 
imaging and neuromelanin MR imaging) and functional 
imaging modalities (99mTc-ethyl cysteinate dimer per-
fusion single photon emission computed tomography, 
123I-metaiodobenzylguanidine myocardial scintigraphy, 
and 123I-FP-CIT dopamine transporter single photon 
emission computed tomography) that are clinically 
available in most hospitals. We also attempt to provide a 
diagnostic approach for the differential diagnosis of PD 
and its related diseases in clinical practice.
Key words    atypical parkinsonian syndrome; 
123I -F P- CI T dopa m i ne t r a nspor t e r i mag i ng; 
123I-metaiodobenzylguanidine myocardial scintigraphy; 
neuromelanin-sensitive MR imaging; Parkinson’s dis-
ease
An accurate diagnosis of Parkinson’s disease (PD) is 
a pre-requisite for patient therapeutic management. 
However, the overall quality of the clinical diagnosis 
of PD is inadequate, even in tertiary centers with 
movement disorder experts. Only 8 out of 10 patients 
with parkinsonism have a valid diagnosis.1, 2 In early 
disease stages, the differentiation between PD and 
atypical parkinsonian syndromes such as dementia with 
Lewy bodies (DLB), multiple system atrophy (MSA), 
progressive supranuclear palsy (PSP), and corticobasal 
degeneration (CBD), caused by nigrostriatal degenera-
tion may be challenging in clinical practice.3 PD may 
also be mimicked by syndromes not associated with a 
striatal dopamine deficiency such as essential tremor 
(ET), drug-induced parkinsonism, and vascular parkin-
sonism (VP).4, 5 Moreover, difficulties are sometimes 
associated with the clinical differentiation of patients 
with parkinsonism from those with Alzheimer’s disease 
(AD) because of overlapping clinical and pathological 
features.2, 6, 7
 In spite of recent advances in the imaging and 
genetics of parkinsonian disorders, the diagnosis of PD 
remains a primarily clinical exercise. In an attempt to 
target this pitfall, numerous ancillary investigations have 
been developed in the last decade to support a PD diag-
nostic work-up.1 Postuma et al. have recently proposed 
criteria intended to be used as the official International 
Parkinson and Movement Disorder Society (MDS) 
Clinical Diagnostic Criteria for PD (MDS-PD Criteria).8 
However, neuroimaging findings play only a limited role 
in this criteria. Strategies to develop biomarkers for the 
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diagnosis of PD, particularly to enable a diagnosis early 
in the disease course, even before the onset of motor 
symptoms, are still under investigation.9 
 The aim of this review is to describe typical neuro-
imaging findings of PD and its related diseases. We also 
stress the significance of neuroimaging in the differential 
diagnosis of PD and its related diseases and attempt to 
provide a diagnostic approach for a differential diagnosis 
in clinical practice.
PD AND ITS RELATED DISEASES
The majority of neurodegenerative diseases have been 
characterized by the deposition of insoluble protein in 
the brain. α-Synuclein is a major component of Lewy 
bodies and tau is a principal component of neurofibril-
lary and glial tangles. Synucleinopathies are neuro-
degenerative diseases characterized by the abnormal 
accumulation of aggregates of α-synuclein in neurons, 
nerve fibers or glial cells. Tauopathies are a class of neu-
rodegenerative diseases associated with the pathological 
aggregation of tau protein in neurofibrillary or glio-
fibrillary tangle. Main tauopathies consist of PSP, CBD, 
AD, and frontotemporal degeneration, while the main 
synucleinopathies with parkinsonism are PD, DLB, and 
MSA.
 Parkinsonian syndromes are a group of movement 
disorders characterized by classical motor symptoms 
such as tremors, bradykinesia, and rigidity. They are 
most frequently due to primary neurodegenerative 
disease, resulting in the loss of dopaminergic nerve 
terminals along the nigrostriatal pathway, similar to 
idiopathic PD, MSA, PSP, CBD, and DLB. Other causes 
of parkinsonism that do not involve nigrostriatal degen-
eration include drug-induced, vascular, and psychogenic 
diseases as well as ET.10 
 Non-motor features such as cognitive impairment 
are common in early PD. Dementia is particularly preva-
lent, occurring in 83% of patients with PD who have had 
a disease duration of 20 years.9 Therefore, PD and its 
related neurodegenerative diseases may also be included 
in the differential diagnosis of dementia. The clinical 
distinction between DLB and AD is sometimes difficult 
and DLB is most often misdiagnosed as AD.11 
 From the viewpoint of clinical differentiation, this 
review includes PD, atypical parkinsonian disorders 
(DLB, MSA, PSP, and CBD), ET, VP, and AD. 
IMAGING TECHNIQUES
Advances have been made in neuroimaging techniques 
for atypical parkinsonism in recent years. Neuroimaging 
findings may strongly support clinical diagnoses, which 
is crucial for prospective care planning. Nevertheless, in-
creasing information on the mixed pathologies and over-
lapping clinical presentations of these disorders make 
precise differentiation difficult.12 Standardized imaging 
protocols for anatomic and functional imaging of the 
brain are essential for the reliable and accurate diagnosis 
of PD and its related diseases as well as for longitudinal 
studies evaluating disease progression in the clinical and 
research realms.13 Berg et al. stressed an urgent need for 
reassessing the definition including neuroimaging for the 
diagnosis of PD.14
 Conventional MR imaging may show abnormalities 
that are suggestive of neurodegenerative atypical parkin-
sonism.15 Robust data emerging from routine MR imag-
ing and many advanced MR imaging techniques such 
as diffusion-weighted imaging, diffusion-tensor imaging 
(DTI), magnetic resonance spectroscopy, voxel-based 
morphometry (VBM), susceptibility-weighted imaging, 
and neuromelanin-sensitive MR imaging (NmMRI) 
may contribute to a differential diagnosis. Kitao et al. re-
ported that NmMRI visualizes neuromelanin-containing 
neurons in the substantia nigra pars compacta and is use-
ful for the evaluation of parkinsonism.16 The diagnosis of 
PD and its neurodegenerative diseases may be improved 
by applying new MR imaging techniques and modifying 
the conventional sequences described above. Moreover, 
the use of 7T MR imaging scanners may strengthen the 
diagnostic value, but are not yet widely available.12, 17, 18
 In contrast, molecular imaging techniques may 
provide useful neurochemical information for learning 
about the pathophysiology of the disorder, diagnosing 
conditions at the early stages, monitoring disease pro-
gression, and planning and assessing responses to med-
ical and surgical interventions, including the identifica-
tion of potential targets for neuromodulation. In recent 
decades, positron emission computed tomography (PET) 
molecular imaging has provided a better understanding 
of the pathophysiological mechanisms underlying atyp-
ical parkinsonism.19 However, PET typically depends 
on an adjacent cyclotron. Thus, the availability of single 
photon emission computed tomography (SPECT) is 
generally greater than that of PET.20 Regional brain 
perfusion has been extensively investigated with the 
SPECT tracer 99mTc-hexamethyl propylene amine oxime 
(HMPAO).20 123I-metaiodobenzylguanidine (MIBG) 
myocardial scintigraphy and 123I-2β-carbomethoxy-3β-
(4-iodophenyl)-N-(3-fluoropropyl) nortropane (FP-CIT) 
dopamine transporter SPECT (DaTSCAN) may become 
more widely available to assist in the diagnosis of pa-
tients with parkinsonian syndromes in many hospitals, 
because positive cardiac sympathetic denervation on 
MIBG myocardial scintigraphy is taken up for support-
ive criteria and normal presynaptic dopaminergic system 
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Fig. 1. Parkinson’s disease in a 65-year-old female. (a) A T2-weighted MR image demonstrates no defi nite abnormalities including the 
midbrain. (b, c) NmMRI shows decreased hyperintensity in the lateral part of the substantia nigra (arrowheads) and locus coeruleus 
(arrowheads). (d) Markedly decreased striatal DaT uptake (arrows) is observed, particularly on the right side. (e) Perfusion SPECT shows 
mild hypoperfusion of the right basal ganglia (arrow). (f) Myocardial MIBG uptake (arrow) is markedly decreased. DaT, dopamine trans-
porter; MIBG, 123I-metaiodobenzylguanidine; NmMRI, neuromelanin-sensitive MR imaging; SPECT, single photon emission computed 
tomography. 
on DaTSCAN is taken up for absolute exclusion criteria 
in MDS-PD criteria.8
 In this review, we mainly describe the imaging 
findings on conventional MR imaging, NmMRI and 
perfusion SPECT, DaTSCAN, and MIBG myocardial 
scintigraphy of PD and its related diseases.
IMAGING FINDINGS
PD (Fig. 1)
Conventional MR imaging is generally not helpful in the 
diagnosis of early PD because it frequently yields nor-
mal fi ndings.21 Since conventional MR imaging is useful 
for the appreciation of features suggestive of atypical 
parkinsonian disorders, the primary use of MR imaging 
is to exclude specifi c structural abnormalities that may 
potentially mimic PD.22 
 Magnetization transfer MR imaging and DTI demon-
strated a lower magnetization transfer ratio and fractional 
anisotropy in the substantia nigra of PD patients than in 
healthy controls.22 VBM in patients with PD indicates 
a paucity of gray matter atrophy in the early clinical 
phase.22 Although these findings are useful as a group 
study, their application to individual patients may be diffi -
cult. NmMRI shows reductions in the hyperintense signal 
in the substantia nigra, particularly its lateral portion, and 
in the locus coeruleus. These fi ndings are useful for the 
diagnosis and evaluation of the disease progression of 
PD.16, 23, 24 The visualization of nigrosome 1, a substruc-
ture of the substantia nigra pars compacta undergoing 
the greatest and earliest dopaminergic cell loss in PD, on 
MR imaging is expected to result in the development of a 
neuroimaging diagnostic test for PD.5, 25, 26
 DaTSCAN demonstrates nigrostriatal dysfunction 
typical of PD as a decrease in the uptake of the radio-
tracer in the neostriatum with a predominantly early 
deficiency in the putamen and often an asymmetric dis-
tribution.27 Dopamine transporter (DaT) uptake is more 
prominently reduced in the putamen than in the caudate. 
DaTSCAN may accurately differentiate between early 
PD and secondary parkinsonian conditions, namely 
vascular or drug-induced parkinsonism and ET.27 
However, DaTSCAN approaches alone are not suffi cient 
to diagnose PD because they do not reliably distinguish 
PD from other parkinsonian syndromes associated with 
nigrostriatal degeneration, such as atypical parkinson-
ism.9
 PD shows a characteristic impairment in adrenergic 
function that may be demonstrated by simple planar 
scintigraphy of the chest to reveal the lack of myocardial 
MIBG uptake.22 This abnormality is not observed in oth-
er types of neurodegenerative parkinsonisms including 
PSP, MSA, and CBD.22 Therefore, MIBG myocardial 
scintigraphy is useful for differentiating PD from other 
parkinsonisms, particularly neurodegenerative parkin-
sonism. Perfusion SPECT using statistical parametric 
mapping in PD patients compared with healthy subjects 
showed signifi cant hypoperfusion in the basal ganglia, 
thalami, prefrontal and lateral frontal cortex, and pa-
rietooccipital cortex.28 However, perfusion patterns in 
PD patients are different in dominant symptoms and the 
early or late stage.29, 30 Large variations in fi ndings make 
it diffi cult to use brain perfusion SPECT to facilitate the 
differential diagnosis of PD.31 
DLB (Fig. 2)
DLB is an atypical parkinsonian disorder recognized as 
the second most common cause of degenerative demen-
tia in older individuals following AD. Conventional MR 
imaging is of little value for the diagnosis of DLB. MR 
imaging findings in patients with DLB are frequently 
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non-specifi c, with varying patterns of atrophy and white 
matter signal changes.21 A pattern of generalized cortical 
atrophy with notably less atrophy in the hippocampus 
than AD has been reported.32 DTI shows diffusely 
increased mean diffusivity with specifically reduced 
fractional anisotropy in the parietooccipital white mat-
[テキストの入力]  T. Ogawa et al., P.28. 
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Fig. 2. Dementia with Lewy bodies in an 88-year-old male. (a) A T2-weighted MR image demonstrates marked atrophy of the medial 
temporal lobes including the hippocampus. (b, c) NmMRI shows decreased hyperintensity in the lateral part of the substantia nigra 
(arrowheads) and locus coeruleus (arrowheads). (d) Markedly decreased striatal DaT uptake (arrows) is observed. (e) Perfusion SPECT 
shows bilateral occipital hypoperfusion (arrowheads) that is frequently observed in DLB. (f) Markedly decreased myocardial MIBG 
uptake (arrows) is also observed. DaT, dopamine transporter; DLB, dementia with Lewy bodies; MIBG, 123I-metaiodobenzylguanidine; 
NmMRI, neuromelanin-sensitive MR imaging; SPECT, single photon emission computed tomography. 
[テキストの入力]  T. Ogawa et al., P.28. 
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Fig. 3. Multiple system atrophy in a 64-year-old female. (a) A T2-weighted MR image demonstrates cruciform hyperintensity (arrow) in 
the pons, termed the“hot cross bun.” (b, c) NmMRI shows decreased hyperintensity in the substantia nigra (arrowheads) and locus coeru-
leus (arrowheads). (d) Markedly decreased striatal DaT uptake (arrows) is observed. (e) Perfusion SPECT shows marked hypoperfusion 
(arrowheads) in the pons and cerebellum. (f) Myocardial MIBG scintigraphy shows normal myocardial MIBG uptake. DaT, dopamine 
transporter; MIBG, 123I-metaiodobenzylguanidine; NmMRI, neuromelanin-sensitive MR imaging; SPECT, single photon emission com-
puted tomography. 
[テキストの入力]  T. Ogawa et al., P.29. 
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Fig. 4. Progressive supranuclear palsy in a 71-year-old male. (a) A sagittal T1-weighted MR image shows midbrain atrophy with a con-
cave (arrowhead) upper surface (hummingbird sign) compatible with PSP. (b, c) Decreased hyperintensity in the lateral substantia nigra 
(arrowheads) and locus coeruleus (arrowheads) is observed on NmMRI. (d) Decreased DaT uptake in the bilateral putamina (arrows) is 
observed. (e) Perfusion SPECT shows normal perfusion in both basal ganglia. (f) Myocardial MIBG scintigraphy shows normal myocar-
dial MIBG uptake. DaT, dopamine transporter; MIBG, 123I-metaiodobenzylguanidine; NmMRI, neuromelanin-sensitive MR imaging; 
PSP, progressive supranuclear palsy; SPECT, single photon emission computed tomography. 
[テキストの入力]  T. Ogawa et al., P.30. 
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ter, pons, and left thalamus.33 Although these findings 
are useful as a group study, it may be diffi cult to apply 
them to individual patients. On the other hand, NmMRI 
revealed a reduction in the hyperintense signal in the 
substantia nigra, which is useful for the diagnosis of 
nigrostriatal degeneration caused by a striatal dopamine 
defi ciency.16
 DaTSCAN demonstrates variable patterns of de-
creased dopaminergic activity in patients with DLB. 
These patterns are useful for differentiating DLB from 
AD, which demonstrates preserved dopaminergic activ-
ity.21 However, it is not possible to distinguish DLB from 
other atypical parkinsonian disorders such as MSA, PSP, 
and CBD with DaTSCAN due to overlapping patterns.21 
On the other hand, MIBG myocardial scintigraphy is 
useful for differentiating Lewy body-related diseases 
from non-Lewy body diseases including MSA, PSP, 
CBD, AD, vascular dementia, and frontotemporal de-
mentia.34 MIBG myocardial scintigraphy has the poten-
tial to accurately diagnose Lewy body-related disease in 
its preclinical stages, which may be useful for evaluating 
disease-modifying and/or preventive interventions.34
 Occipital hypometabolism is the most distinct 
finding in DLB relative to AD and healthy controls.35 
Reduced occipital metabolism and perfusion are 
supportive features in the 2005 consensus criteria for 
DLB.36 Kantarci et al. reported a relationship between 
occipital hypometabolism and the frequency of visual 
hallucinations, which is one of the three core charac-
teristics of DLB.37 However, occipital hypometabolism 
and hypoperfusion are not always present in neuropatho-
logically confirmed DLB.11, 38 On the other hand, the 
posterior cingulate island sign, which refl ects relatively 
preserved metabolism in the posterior cingulate region, 
is sensitive and specifi c for DLB and is useful for differ-
entiating AD.39
 
MSA (Fig. 3)
MSA consists of two forms: MSA-P – with predom-
inant parkinsonism (80% of patients) and MSA-C – 
with predominant cerebellar ataxia (20% of patients), 
accompanied by dysautonomia in both subtypes.12 
These two clinical variants also differ in terms of brain 
areas involved in the pathological process – in MSA-C, 
neurodegeneration predominately affects the brainstem 
and cerebellum, while in MSA-P, the basal ganglia, 
particularly the putamen, are involved.11 Typical MR 
imaging fi ndings observed in MSA-P are: a hyperintense 
putaminal rim, putaminal atrophy and hypointensity, at-
rophy of and signal decreases in the globus pallidus, and 
infratentorial signal increase and atrophy. In MSA-C, 
the most characteristic changes are: atrophy of the mid-
dle cerebellar peduncle, dilatation of the 4th ventricle, 
atrophy of the pons, and an increased signal within the 
cerebellum, middle cerebellar peduncles, and pons.12 
These changes may produce cruciform T2 hyperinten-
sity within the basis pontis, popularly referred to as the 
hot cross bun sign.21
 The presence of putaminal atrophy appears to help 
discriminate MSA from PD, whereas putaminal T2 
hypointensity is a non-specifi c sign that may also be ob-
served in PSP, Wilson’s disease, neurodegeneration with 
brain iron accumulation, and other acquired conditions.21 
NmMRI revealed a reduction in the hyperintense signal 
in the substantia nigra, which is useful for the diagnosis 
of nigrostriatal degeneration caused by a striatal dopa-
mine defi ciency.16
 DaTSCAN demonstrates reduced striatal dopami-
nergic activity with variable patterns, which may be 
symmetric or asymmetric and affect the putamen or 
caudate nucleus.21 Although a reduction in myocardial 
MIBG may be present in some MSA patients, myocar-
dial MIBG uptake is generally not reduced in MSA. 
Therefore, a high sensitivity of 90.2% and high specifi c-
ity of 81.9% have been reported for differentiating PD 
from MSA.34 Perfusion SPECT shows hypoperfusion 
in the pons and cerebellar hemisphere in MSA-C. 
Asymmetrical cerebellar hypoperfusion is common in 
patients with MSA-C.40
PSP (Fig. 4)
Conventional MR imaging shows midbrain atrophy 
with relative preservation of the pons, which produces 
an appearance sometimes referred to as the “humming-
bird sign” or “penguin sign” on the midsagittal plane, 
with the tegmentum representing the head with a long, 
thin beak, and the pons the body of the hummingbird 
or penguin.13,21 Massey et al. reported that the hum-
mingbird sign on the midsagittal plane with rostral 
midbrain atrophy and concavity was observed in 67% of 
pathologically confi rmed PSP cases.41 PSP has recently 
been recognized to comprise various clinical subtypes, 
except for typical cases (i.e., Richardson’s syndrome).42 
Therefore, the lack of characteristic midbrain atrophy 
on MR imaging is expected. Additional fi ndings include 
superior cerebellar peduncle atrophy and a stronger 
fl uid-attenuated inversion recovery (FLAIR) signal, both 
of which have reasonably high sensitivity and specifi city 
in distinguishing PSP from PD and MSA.21 NmMRI 
also reveals a reduction in the hyperintense signal in the 
substantia nigra and is useful for atypical parkinsonian 
disorders. 
 DaTSCAN shows reduced tracer uptake in the stri-
atum. Striatal DaT is generally decreased more in PSP 
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than in MSA-P and PD with the uniform involvement 
of dopamine terminals in the caudate and putamen.22 
By exploiting the capability of perfusion SPECT to in-
vestigate regional cerebral blood flow and characteristic 
distribution to the medial frontal cortex of pathological 
alterations in PSP, Varrone et al. reported that evidence 
[テキストの入力]  T. Ogawa et al., P.31. 
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Fig. 5. Corticobasal degeneration in a 79-year-old female. (a) A T2-weighted MR image demonstrates diffuse brain atrophy. Widening of 
the right frontal cortical sulci and parietooccipital sulcus are prominent (arrowheads). (b, c) NmMRI shows decreased hyperintensity in 
the lateral part of the substantia nigra (arrowheads) and locus coeruleus (arrowheads). (d) Slightly decreased striatal DaT uptakes (arrow) 
are observed in the right side. (e) Perfusion SPECT shows diffuse hypoperfusion of the cerebral cortex, particularly the right frontal lobe 
(arrowheads) (f) Myocardial MIBG uptake is preserved. DaT, dopamine transporter; MIBG, 123I-metaiodobenzylguanidine; NmMRI, 
neuromelanin-sensitive MR imaging; SPECT, single photon emission computed tomography. 
[テキストの入力]  T. Ogawa et al., P.31. 
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Fig. 6. Essential tremor in an 87-year-old female. (a) A T2-weighted MR image demonstrates no definite abnormalities in the 
midbrain. (b, c) Hyperintense regions in the substantia nigra and locus coeruleus are preserved on NmMRI. (d) DaTSCAN shows 
normal DaT uptake in the bilateral striatum. (e) Perfusion SPECT shows normal perfusion in the cerebral cortices and basal ganglia. (f) 
Myocardial MIBG scintigraphy shows normal myocardial MIBG uptake. DaT, dopamine transporter; DaTSCAN, dopamine trans-
porter SPECT; MIBG, 123I-metaiodobenzylguanidine; NmMRI, neuromelanin-sensitive MR imaging; SPECT, single photon emission 
computed tomography. 
[テキストの入力]  T. Ogawa et al., P.32. 
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Fig. 7. Vascular parkinsonism in an 81-year-old female. (a) A T2-weighted MR image demonstrates small infarcts in the right basal 
ganglia (arrows) and diffuse white matter lesions (arrowheads). (b, c) Hyperintense regions in the substantia nigra and locus coeruleus 
are preserved on NmMRI. (d) DaTSCAN shows normal DaT uptake in the bilateral striatum. (e) Perfusion SPECT shows decreased hy-
poperfusion of the bilateral frontal cortices. (f) Myocardial MIBG scintigraphy shows normal myocardial MIBG uptake. DaT, dopamine 
transporter; DaTSCAN, dopamine transporter SPECT; MIBG, 123I-metaiodobenzylguanidine; NmMRI, neuromelanin-sensitive MR 
imaging; SPECT, single photon emission computed tomography. 
[テキストの入力]  T. Ogawa et al., P.33. 
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of hypoperfusion in the anterior cingulate and medial 
frontal cortex may represent an additional feature to dif-
ferentiate PSP from PD. MIBG myocardial scintigraphy 
is generally normal in PSP.22 This technique is extremely 
useful for differentiating PSP from PD and DLB.
CBD (Fig. 5)
In the early stages of disease, conventional MR imaging 
fi ndings may be subtle, but abnormal. Asymmetric atro-
phy centered in the posterior frontal and parietal lobes 
and corpus callosum atrophy develop in a significant 
proportion of patients. There may also be associated 
atrophy of the ipsilateral cerebral peduncle without 
Wallerian degeneration of the corticospinal tract.13, 21 
However, Lee et al. reported using VBM by MR imag-
ing that many patients with CBD fall within the range 
of asymmetry observed in healthy controls.43 Therefore, 
it is important to note that CBD often has a clinically 
and anatomically symmetric presentation, although 
asymmetry has been stressed as a core feature of CBD. 
T2-weighted and FLAIR images may reveal subcortical 
white matter hyperintensity in the atrophic frontoparietal 
sulci, presumably refl ecting neuronal degeneration.21, 44 
NmMRI reveals a reduction in the hyperintense signal in 
the substantia nigra, refl ecting nigrostriatal degeneration 
caused by a striatal dopamine defi ciency.
 DaTSCAN demonstrates variable decreased putam-
inal activity that, similar to atrophy in MR imaging and 
hypometabolism in 18F-fl uorodeoxyglucose (FDG) PET, 
is often asymmetric and contralateral to the affected 
side.21 This frequently manifests as left-sided cerebral 
hypometabolism in the cortex of right-sided symptoms.13 
A perfusion SPECT study showed asymmetric hypoper-
fusion in the frontoparietal lobes and basal ganglia.22 
In general, MIBG myocardial scintigraphy is normal in 
CBD.22
ET (Fig. 6)
Typical ET cases may be easily diagnosed and distin-
guished from PD. However, the clinical differentiation 
between these conditions may be challenging, and con-
siderable overlap has been reported in clinical features, 
particularly in the early stages of the disease.45 
 Several MR imaging studies have investigated 
anatomical and functional brain alterations in ET pa-
tients, and some pathological studies recently provided 
evidence of structural brain changes in this disease that 
may be associated with neurodegeneration.45 On DTI, 
microstructural changes with neurodegeneration were 
detected in the dentate nucleus and superior cerebellar 
peduncle of patients with familial ET.46 On NmMRI, 
neuromelanin in the substantia nigra was not signifi-
cantly lower than that in the healthy control group in 
ET, whereas PD patients, even at the time of the clinical 
diagnosis, exhibited a significant reduction in the 
substantia nigra, which was more pronounced laterally 
in accordance with pathological changes. Therefore, 
NmMRI may become a useful diagnostic tool for the 
differentiation of ET from PD in very early clinical stag-
es.45
 DaTSCAN discriminates ET and PD because pa-
tients with ET consistently and effectively have normal 
striatal DaT binding. In a meta-analysis of the diagnostic 
differentiation of ET and PD using DaTSCAN, the 
study with the lowest sensitivity and specifi city reported 
percentages of 80% and 95%, respectively.27,47 Regarding 
MIBG myocardial scintigraphy, Lee et al. reported that 
myocardial MIBG uptake in patients with ET was with-
in the normal range and clearly distinguishes them from 
patients with PD.48 
VP (Fig. 7)
As a basic requirement for VP, Zijlmans et al. concluded 
that vascular disease may per se be a cause of par-
kinsonism in the absence of alternative or co-existing 
pathological lesions linked with neurodegenerative 
disease.49 However, a clinical diagnosis of VP is still dif-
fi cult because vascular lesions are a common incidental 
fi nding in pathologically confi rmed PD. As MR imaging 
is important for the diagnosis of VP, MR imaging needs 
to play a complementary role in the diagnosis of VP. 
 Functional imaging is helpful for differentiating 
between parkinsonian syndromes. In the presence of 
vascular lesions on CT/MR imaging (e.g., a “punched 
out” lesion characteristic of an infarct or the diffuse 
white matter disease of ischemia), normal DaTSCAN 
findings are diagnostic of VP.27, 47 A meta-analysis 
of the diagnostic differentiation of PD and VP using 
DaTSCAN demonstrated a sensitivity of 80%–100% and 
specifi city of 73%–100%.47 Regarding MIBG myocardi-
al scintigraphy, Navarro-Otano et al. demonstrated from 
the evaluation of a relatively small sample size that this 
method was useful for differentiating between VP and 
PD when the fi ndings of DaTSCAN were confusing.50 
AD (Fig. 8)
AD is the most common cause of dementia. AD is 
generally not included in the differential diagnosis of 
parkinsonism. However, differentiating between AD and 
DLB or Parkinson’s disease dementia is challenging if 
dementia precedes motor symptoms. In some cases, the 
clinical differentiation of patients with AD from those 
with DLB may be diffi cult because of overlapping clini-
cal and pathological features.6 
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 Conventional MR imaging shows focal volume loss 
classically starting in the entorhinal cortex, involving 
the medial temporal lobe and hippocampus, as well as 
the parietal lobe in AD.51 NmMRI shows no reduction 
in signal intensity in the substantia nigra in AD, while a 
signal reduction in the substantia nigra is prominent in 
patients with PD and DLB. These fi ndings are useful for 
the differentiation of AD from DLB.23, 24
 Hypometabolism and hypoperfusion on FDG PET 
and perfusion SPECT may be detected before the onset 
of clinical symptoms, showing a typical topographic 
pattern: the posterior cingulate-precuneus region is 
affected fi rst, followed by the lateral temporoparietal re-
gion. 11C-PIB PET shows increased cortical uptake with 
the highest retention in the frontal, cingulate, precuneus, 
striatum, parietal and lateral temporal cortex.51, 52
 Recent studies have indicated that MIBG myocar-
dial scintigraphy provides diagnostic information that is 
useful for differentiating DLB from AD.6 Moreover, the 
combination of DaTSCAN and MIBG myocardial scin-
tigraphy may provide a powerful differential diagnostic 
tool when it is difficult to differentiate patients with 
DLB from those with AD using DaTSCAN or MIBG 
myocardial scintigraphy alone.6
DIFFERENTIATION OF PD AND ITS RELATED 
DISEASES BY NEUROIMAGING (Fig. 9)
Although the gold standard for the diagnosis of PD and 
its related neurodegenerative diseases is a postmortem 
neuropathological examination27, the diagnosis of these 
diseases is still largely based on the correct identifi cation 
of their clinical features.1 In spite of advances in clini-
cally available anatomical and functional neuroimaging, 
these neuroimaging fi ndings in the consensus guidelines 
for the diagnosis are extremely limited. However, recent 
advances in neuroimaging may highlight the need for 
radiologists to become familiar with these imaging fi nd-
ings.
 MR imaging is easily available in most hospitals. 
SPECT systems are generally less expensive and more 
widely available in most hospitals than PET instruments. 
Therefore, we provide a practical diagnostic approach 
for PD and its related diseases using MR imaging and 
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Fig. 8. Alzheimer’s disease in an 80-year-old male. (a) A T2-weighted MR image demonstrates marked atrophy of the bilateral temporal 
lobes including the hippocampus (arrows). (b, c) Hyperintense regions in the substantia nigra and locus coeruleus are preserved on 
NmMRI. (d) DaTSCAN shows normal DaT uptake in the bilateral striatum. (e) Perfusion SPECT shows marked hypoperfusion in the 
bilateral temporal lobes (arrowheads). (f) There are no abnormalities on myocardial MIBG scintigraphy. DaT, dopamine transporter; 
DaTSCAN, dopamine transporter SPECT; MIBG, 123I-metaiodobenzylguanidine; NmMRI, neuromelanin-sensitive MR imaging; 
SPECT, single photon emission computed tomography. 
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 Fig. 9. A diagnostic algorithm using neuroimaging for PD and 
its related diseases. AD, Alzheimer’s disease; CBD, corticobasal 
degeneration; DaTSCAN, dopamine transporter SPECT; DLB, 
dementia with Lewy bodies; ET, essential tremor; MIBG, 
123I-metaiodobenzylguanidine; MSA, multiple system atrophy; 
NmMRI, neuromelanin-sensitive MR imaging; PD, Parkinson’s 
disease; PSP, progressive supranuclear palsy; SI, signal intensity; 
SN, substantia nigra; SPECT; single photon emission computed 
tomography; VP, vascular parkinsonism.
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MIBG myocardial scintigraphy and SPECT in this 
review. However, we must get the attention of readers 
in the following respects in the evaluation of molecular 
imaging such as SPECT. Several therapeutic drugs, 
symptom duration, and patient age can affect the uptake 
of radiotracers in the target organs.53–55 For the quanti-
tative evaluation of uptake of radiotracer, it is important 
to recognize the difference between the gamma camera 
systems including collimators.
 With the above in mind, first, conventional MR 
imaging and NmMRI should be applied to the patients 
with movement disorders and/or dementia. Second, 
DaTSCAN or MIBG myocardial scintigraphy should 
be selected according to these MR imaging findings. 
Moreover, a combination of these neuroimaging meth-
ods is a useful and practical approach for the differential 
diagnosis and confirmation of PD and its related dis-
eases. However, we also stress that we should select the 
neuroimaging modality easily available in your hospital 
with knowledge of the neuroimaging fi ndings mentioned 
above in mind for its differentiation.
CONCLUSION
A combination of clinical features with MR imaging 
and MIBG myocardial scintigraphy and/or DaTSCAN 
is recommended for optimization of the diagnostic algo-
rithm in PD and its related diseases. 
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